HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ZLAB
Zai Lab Limited
ZLAB lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ZLAB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Unavailable |
ZLAB's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ZLAB PE Valuation
ZLAB has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ZLAB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect ZLAB's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ZLAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.19 | +$0.01 |
| Q2 2026 | -$0.18 | +$0.03 |
| Q1 2026 | -$0.17 | +$0.08 |
| Q4 2025 | -$0.16 | +$0.10 |
| Q3 2025 | -$0.20 | +$0.07 |
| Q2 2025 | -$0.21 | +$0.09 |
| Q1 2025 | -$0.25 | +$0.10 |
| Q4 2024 | -$0.26 | +$0.09 |
ZLAB has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ZLAB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ZLAB on profitability, with a higher operating margin.
ZLAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $108.2M | -6.8% |
| Q2 2026 | $106.3M | -3.3% |
| Q1 2026 | $99.6M | -6.5% |
| Q4 2025 | $127.6M | +17% |
| Q3 2025 | $116.1M | +14% |
| Q2 2025 | $110M | +9.4% |
| Q1 2025 | $106.5M | +22% |
| Q4 2024 | $109.1M | +66% |
ZLAB's revenue has held roughly level: $108M last quarter, down 6.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -58% | -16 points |
| Q2 2026 | -72% | -22 points |
| Q1 2026 | -70% | -17 points |
| Q4 2025 | -54% | +7.9 points |
| Q3 2025 | -42% | +24 points |
| Q2 2025 | -50% | +26 points |
| Q1 2025 | -53% | +28 points |
| Q4 2024 | -62% | +126 points |
ZLAB's operating margin was −58% last quarter, down 16 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ZLAB on cash generation, producing positive trailing cash flow while its opponent burns cash.
ZLAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$58.8M | -$23.8M |
| Q2 2026 | -$64.7M | -$30.8M |
| Q1 2026 | -$13.1M | +$50.1M |
| Q4 2025 | -$26.7M | +$31.7M |
| Q3 2025 | -$35M | -$6.9M |
| Q2 2025 | -$33.9M | +$9M |
| Q1 2025 | -$63.2M | +$27.8M |
| Q4 2024 | -$58.4M | -$43.2M |
ZLAB has burned cash in almost every quarter: −$163M over the past year, against −$191M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ZLAB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ZLAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +6.4M shares |
| 1 year | +1.9% | +21.3M shares |
| 3 years | +16% | +155M shares |
ZLAB has 1.1B diluted shares, up 1.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ZLAB Net Leverage
ZLAB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ZLAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.3 | Neutral |
| Stochastic | 60.8 | Neutral |
ZLAB's weekly RSI is 58 (neutral) and its Stochastic is 61 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ZLAB PE vs Healthcare Sector
ZLAB has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ZLAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $24.4 | 6.8% above |
| 20 week MA | $23.5 | 11% above |
| 50 week MA | $20.8 | 25% above |
| 100 week MA | $25.9 | 0.5% above |
| 200 week MA | $25.8 | 0.8% above |
ZLAB has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
ZLAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.3 | $133.8 | +232% |
| 2021 | $133.8 | $65.8 | -51% |
| 2022 | $65.8 | $30.8 | -53% |
| 2023 | $30.8 | $27.3 | -11% |
| 2024 | $27.3 | $26.6 | -2.6% |
| 2025 | $26.6 | $18.3 | -31% |
| 2026 YTD | $18.3 | $26.0 | +42% |
ZLAB has the edge over HIMS on returns for 2026, with the stronger performance.